还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

1 t- f5 o" I0 Z2 U( y5 G* `                               
登录/注册后可看大图

8 q6 B, ?6 Z4 b' _0 H0 `* ~请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

, L. d/ o3 G; t. ?可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
" o4 E+ x$ w( F" S2 _$ s( q2 C
3 B% |+ }8 b6 K
Sub-category:
Molecular Targets


Category:
& i5 p3 K. N2 `+ UTumor Biology


4 f' b$ S% F# i7 G) aMeeting:
2011 ASCO Annual Meeting


7 G9 G% j. O0 R. I$ p* E- USession Type and Session Title:
7 g8 f% V  O: QPoster Discussion Session, Tumor Biology


Abstract No:
10517
! C5 m& M/ o8 Y

Citation:
" B3 s7 n/ I( l6 o& KJ Clin Oncol 29: 2011 (suppl; abstr 10517)
3 E9 k+ W1 o5 S4 o( Q/ }  y

0 X5 ^7 K# R3 z* W5 E. ZAuthor(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


+ X* o+ t& o4 [! x+ S7 V9 Y
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
' b8 b, e8 K+ B1 V- f( d$ I
+ n& C# f( ]$ x& h8 C( eAbstract Disclosures

Abstract:
7 k6 F1 L* k- X0 M* e: t# [# X
/ p7 _0 w5 ~# Z9 P/ W
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ n0 A9 Z3 J0 h. V5 I  T

) I7 V4 q" @  A3 Y" z& a0 T) ]6 X; p

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

7 {* V* |; d! a( d! n3 I                               
登录/注册后可看大图

3 U: `( ~' g; H; m- g没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
! H7 y$ }4 @/ e+ ~ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

# L5 t7 W) j1 O7 M4 e3 d现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊